In light of observed results of those ILK mutants, we then tested the effects of the ILK specific inhibitor, CPD22, in cellular senescence, which was known to have in vitro anti-proliferative potency against a few human cancer cells at IC50 (2–5 μM) [24] and we tested the IC50 in MKN1 and MKN28 cell lines (Supplementary Fig. S8A). The gene discussed is ILK; the disease is cancer.